natgillin/translations-raw huggingface dataset:
The pharmaceutical composition according to claim 19 wherein said substances which potentiate the cytotoxic effect of the 5-Fluorocytosine are drugs which inhibit the enzymes of the pathway for the de novo biosynthesis of the pyrimidines, preferably selected from the group consisting of PALA, Leflunomide and A771726. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 19, naznačen time što su navedene tvari koje pojačavaju citotoksični učinak 5-fluorcitozina lijekovi koji inhibiraju enzime u putu biosinteze pirimidina de novo, koje se po mogućnosti bira iz skupine koju čine PALA, leflunomid i A771726.
The pharmaceutical composition according to claim 19 wherein said substance which potentiate the cytotoxic effect of the 5-Fluorocytosine is methotrexate. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 19, naznačen time što je navedena tvar koja pojačava citotoksični učinak 5-fluorcitozina metotreksat.
The pharmaceutical composition according to any one of claims 18 to 21 for use in the treatment of a proliferative disease or a disease associated with an increased osteoclast activity. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 18 do 21, naznačen time što je namijenjen upotrebi u liječenju proliferativne bolesti ili bolesti povezane s pojačanom aktivnošću osteoklasta.
The poxvirus for use in the treatment of a proliferative disease or a disease associated with an increased osteoclast activity according to claim 16 or the pharmaceutical composition for use in the treatment of a proliferative disease or a disease associated with an increased osteoclast activity according to claim 22, wherein the proliferative disease is cancer or restenosis. 
Poksvirus, namijenjen upotrebi u liječenju proliferativne bolesti ili bolesti povezane s pojačanom aktivnošću osteoklasta u skladu s patentnim zahtjevom, 16 ili farmaceutski pripravak, namijenjen upotrebi u liječenju proliferativne bolesti ili bolesti povezane s pojačanom aktivnošću osteoklasta u skladu s patentnim zahtjevom 22, naznačeni time što je proliferativna bolest rak ili restenoza.
The poxvirus for use in the treatment of a proliferative disease or a disease associated with an increased osteoclast activity according to claim 16 or the pharmaceutical composition for use in the treatment of a proliferative disease or a disease associated with an increased osteoclast activity according to claim 22, wherein the disease associated with an increased osteoclast activity is rheumatoid arthritis or osteoporosis 
Poksvirus, namijenjen upotrebi u liječenju proliferativne bolesti ili bolesti povezane s pojačanom aktivnošću osteoklasta u skladu s patentnim zahtjevom, 16 ili farmaceutski pripravak, namijenjen upotrebi u liječenju proliferativne bolesti ili bolesti povezane s pojačanom aktivnošću osteoklasta u skladu s patentnim zahtjevom 22, naznačeni time je bolest povezana s pojačanom aktivnošću osteoklasta reumatoidni artritis ili osteoporoza.
The pharmaceutical composition for use in the treatment of a proliferative disease or a disease associated with an increased osteoclast activity according to claim 26, wherein the administration of said prodrug takes place at least 3 days, preferably at least 4 days and more preferably at least 5 days after the administration of said poxvirus or composition. 
Farmaceutski pripravak, namijenjen upotrebi u liječenju proliferativne bolesti ili bolesti povezane s pojačanom aktivnošću osteoklasta u skladu s patentnim zahtjevom 26, naznačen time što se navedeni predlijek primjenjuje najmanje 3 dana, po mogućnosti najmanje 4 dana, a poželjnije najmanje 5 dana nakon primjene navedenog poksvirusa ili pripravka.
The pharmaceutical composition for use in the treatment of a proliferative disease or a disease associated with an increased osteoclast activity according to claim 27 wherein the administration of said prodrug takes place 7 days after the administration of said poxvirus or composition. 
Farmaceutski pripravak, namijenjen upotrebi u liječenju proliferativne bolesti ili bolesti povezane s pojačanom aktivnošću osteoklasta u skladu s patentnim zahtjevom 27, naznačen time što se navedeni predlijek primjenjuje 7 dana nakon primjene navedenog poksvirusa ili pripravka.
wherein the term "heterocyclyl moiety" refers to a monovalent saturated or partially saturated 3- to 7-membered monocyclic or 9- to 10-membered bicyclic ring system wherein one, two, three or four ring carbon atoms have been replaced by N, O or S, and with the attachment point on the saturated or partially unsaturated ring of said ring system; 
gdje se izraz "heterociklil" odnosi na monovalentni zasićeni ili djelomično zasićeni 3-člani do 7-člani monociklički ili 9-člani do 10-člani biciklički prstenasti sustav, pri čemu se jedan, dva, tri ili četiri atoma ugljika u prstenu zamjenjuju s N, O ili S, i s točkom priključenja na zasićenom ili djelomično nezasićenom prstenu od navedenog prstenastog sustava; ili njegova farmaceutski prihvatljiva sol.
A composition comprising the antibody or antigen-binding portion of any one of claims 1 to 4, the immunoconjugate of claim 5 or 6 or bispecific molecule of claim 7, and a pharmaceutically acceptable carrier. 
Kompozicija koja sadrži antitijelo ili antigen-vežući dio prema bilo kojem od patentnih zahtjeva 1 do 4, imunokonjugat prema patentnom zahtjevu 6 ili bispecifičnu molekulu prema patentnom zahtjevu 7, i farmaceutski prihvatljiv nosač.
drying the absorptive layer and the topcoat, wherein the absorptive layer and the topcoat are either dried simultaneously or the absorptive layer is dried after step b) and before applying the topcoat according to step c) wherein the topcoat has a permeability of greater than 5.0x 10-18 m2, and wherein the absorptive layer has an absorption rate from 1×10-5 ms-0.5 to 1×10-3 ms-0.5 and/or a volume uptake from 30 to 95 % by volume relative to the total volume of the absorptive layer. 
sušenje apsorpcijskog sloja i završnog premaza, pri čemu se apsorpcijski sloj i završni premaz suše istodobno ili se apsorpcijski sloj suši nakon koraka b) i prije nanošenja završnog premaza u koraku c) pri čemu završni premaz ima propusnost veću od 5.0×10-18 m2 i sadrži kalcijev karbonat, i pri čemu apsorpcijski sloj ima stupanj upijanja od 1×10-5 ms-0.5 do 1×10-3 ms-0.5 i/ili unos volumena od 30 do 95 % volumena u odnosu na ukupni volumen apsorpcijskog sloja.
The method of claim 17, wherein steps b) to d) are also carried out on the reverse side of the base layer to manufacture a print medium being coated on the first side and the reverse side. 
Postupak prema zahtjevu 17, naznačen time da se koraci b) do d) također provode na stražnjoj strani osnovnog sloja kako bi se proizvela tiskovna podloga koja je premazana na prvoj strani i stražnjoj strani.
The method of claims 17 or 18, wherein the liquid coating formulation used to form an absorptive layer and/or a topcoat has a solid content of 10 to 80 wt.-%, preferably of 30 to 60 wt.-%, and more preferably of 45 to 55 wt.-% based on the total weight of the formulation. 
Postupak prema zahtjevima 17 ili 18, naznačen time da tekuća formulacija premaza koji se koristi za dobivanje apsorpcijskog sloja i/ili završnog premaza koji ima sadržaj krutih tvari od 10 do 80 tež.-%, poželjno od 30 do 60 tež.-%, i poželjnije od 45 do 55 tež.-% u odnosu na ukupnu težinu formulacije.
The method of claims 17 to 22, wherein the coating formulations are applied by high speed coating, meter size press, curtain coating, spray coating, or electrostatic coating, and preferably by high speed coating. 
Postupak prema zahtjevima 17 do 22, naznačena time da se formulacije premaza nanose premazivanjem pri visokoj brzini, film prešom, tekućom zavjesom, raspršivanjem ili elektrostatski, i poželjno premazivanjem pri visokoj brzini.
The process of any of claims 1, 3, 4, wherein the polar solvent is selected from the group comprising organic solvents containing at least one hydroxyl group, tetrahydrofuran, ethyl acetate or mixtures thereof. 
Postupak prema bilo kojem zahtjevu 1, 3, 4, naznačen time da je polarno otapalo odabrano is skupine koja sadrži organska otapala koja sadrže najmanje jednu hidroksilnu skupinu, tetrahidrofuran, etil acetat ili njihove mješavine.
The process of any of claims 1, 3, 4, wherein the polar solvent is selected from the group comprising organic solvents containing methanol, ethanol, n-pronanol, isopropanol, n-butanol, sec-butanol, n-pentanol, glycerol, ethylene glycol, dioxane, dimethoxyethane, tetrahydrofuran, ethyl acetate or mixtures thereof. 
Postupak prema bilo kojem zahtjevu 1, 3, 4, naznačen time da je polarno otapalo odabrano is skupine koja sadrži organska otapala koja sadrže metanol, etanol, n-propanol, izopropanol, n-butanol, sek-butanol, n-pentanol, glicerol, etilen glikol, dioksan, dimetoksietan, tetrahidrofuran, etil acetat ili njihove mješavine.
The process of any of claims 1 to 6, wherein the compound of the formula (V) is prepared by reacting the compound of the formula (IV) with 4-aminophenol without adding a carbonate salt. 
Postupak prema bilo kojem zahtjevu od 1 do 6, naznačen time da se spoj s formulom (V) priprema reakcijom spoja s formulom (IV) [image] -aminofenolom bez dodavanja soli karbonata.
The process of claim 7 or 8, wherein the compound of the formula (IV) is prepared by reacting the compound of the formula (III) with an aqueous methylamine solution. 
Postupak prema zahtjevu 7 ili 8, naznačen time da se spoj s formulom (IV) priprema reakcijom spoja s formulom (III) [image] s vodenom otopinom metilamina.
The process of claim 9, wherein the compound of the formula (III) is prepared by using a solvent inert toward thionyl chloride, adding thionyl chloride to 2-picolinic acid and without using of dimethylformamide. 
Postupak prema zahtjevu 9, naznačen time da se spoj s formulom (III) pripravlja upotrebom otapala inertnog prema tionil kloridu, dodavanjem tionil klorida u 2-pikolinsku kiselinu i bez upotrebe dimetilformamida.
reacting the compound of the formula (IV) with 4-aminophenol without adding a carbonate salt to give the compound of the formula (V), 
reakcije spoja s formulom (IV) s 4-aminofenolom bez dodavanja soli karbonata da se dobije spoj s formulom (V),
reacting the compound of the formula (IV) with 4-aminophenol to give the compound of the formula (V), 
reakcije spoja s formulom (IV) s 4-aminofenolom da se dobije spoj s formulom (V),
adding thionyl chloride to 2-picolinic acid in a solvent inert toward thionyl chloride without using dimethylformamide and reacting to give the compound of the formula (III), 
dodavanja tionil klorida u 2-pikolinsku kiselinu u otapalu koje je inertno prema tionil kloridu bez upotrebe dimetilformamida uz reakciju da se dobije spoj s formulom (III),
reacting the compound of the formula (III) with methylamine to give the compound of the formula (IV), 
reakcije spoja s formulom (III) s metilaminom da se dobije spoj s formulom (IV),
The crystalline form according to claim 6 or 7, which has a melting point of 133±5 °C as determined by differential scanning calorimetry using a heating rate of 10°C min-1. 
Kristalni oblik prema zahtjevu 6 ili 7, naznačen time, da ima talište na 133 ± 5°C, koje je određeno kalorimetrijskim diferencijalnim skeniranjem koristeći brzinu zagrijavanja od 10°C min-1.
ii) equilibrating the internal temperature at 58°C with paddle stirring at 350 rpm; 
ii) ekvilibriranje unutrašnje temperature na 58°C s lopatastim miješanjem na 350 rpm;
iii) adding deionised water (1.0 L) in 250 mL aliquots (minimum internal temperature = 45°C) yielding a clear solution on mixing; 
iii) dodavanje deionizirane vode (1,0 L) u 250 mL alikvota (minimalna unutrašnja temperatura = 45°C), čime se pridonosi bistroj otopini pri miješanju;
iv) allowing the internal temperature to reach 55°C and adding one additional aliquot of water (250 mL) yielding a clear solution on mixing; 
iv) omogućavanje dosizanja unutrašnje temperature na 55°C i dodavanje jednog dodatnog alikvota vode (250 mL), čime se pridonosi bistroj otopini pri miješanju;
vi) cooling the solution to 12°C over about 2 hours (cooling rate = 0.4°C/min); and vii) stirring the suspension at 12°C for 18 hours. 
vi) hlađenje otopine na 12°C za vrijeme oko 2 sata (brzina hlađenja = 0,4°C/min); i vii) miješanje suspenzije na 12°C u trajanju od 18 sati.
ii) stirring with a mechanical stirrer at room temperature yielding a highly viscous paste that transforms to a thin fluid suspension of distinct yellow colour after stirring for 40 hours; and 
ii) miješanje s mehaničkim mikserom na sobnoj temperaturi dobivajući kašu velike viskoznosti, koja se transformira u tanku fluidnu suspenziju izrazito žute boje nakon miješanja u trajanju od 40 sati; i
iii) filtering off the solid and drying the same for 4 hours under vaccum at room temperature. 
filtriranje od krutina i sušenje u vremenu od 4 sata pod vakuumom na sobnoj temperaturi.
A pharmaceutical composition comprising a crystalline form according to any one of claims 1 to 10 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća kristalni oblik prema bilo kojem od zahtjeva 1 do 10 i farmaceutski prihvatljiv nosač.
A crystalline form according to any one of claims 1 to 10, or a pharmaceutical composition according to claim 11, for use in the prevention or treatment of diseases or disorders selected from the group consisting of rejection of transplanted organs such as kidney, liver, heart, lung, pancreas, cornea, and skin; graft-versus-host diseases brought about by stem cell transplantation; autoimmune syndromes including rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, psoriasis, psoriatic arthritis, thyroiditis such as Hashimoto's thyroiditis, and uveo-retinitis; atopic diseases such as rhinitis, conjunctivitis, and dermatitis; asthma; type I diabetes; post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis; solid cancers; and tumor metastasis. 
Kristalni oblik prema bilo kojem od zahtjeva 1 do 10, ili farmaceutski sastav prema zahtjevu 11, naznačen time, da se upotrebljava za prevenciju ili liječenje bolesti ili poremećaja odabranih iz skupine koja se sastoji od sljedećih: odbacivanje transplantiranih organa kao što su bubreg, jetra, srce, pluća, gušterača, rožnica i koža; usadak protiv stanice domaćina uzrokovan transplantacijom matične stanice; autoimuni sindromi uključujući reumatoidni artritis, multiplu sklerozu, upalnu bolest crijeva kao što su Chronova bolest i ulcerativni kolitis; psorijaza, psorijatični artritis, tiroiditis kao što su Hashimotoov tiroiditis i uveo-retinitis; atopijske bolesti kao što su rinitis, konjunktivitis i dermatitis; astma; dijabetes tipa I; autoimune bolesti nakon infekcija uključujući reumatsku groznicu i post-infektivni glomerulonefritis; čvrsti tumori; i tumorske metastaze.
A crystalline form according to any one of claims 1 to 10, or a pharmaceutical composition according to claim 11, for use in the prevention or treatment of diseases or disorders selected from the group consisting of rejection of transplanted organs selected from kidney, liver, heart and lung; graft-versus-host diseases brought about by stem cell transplantation; autoimmune syndromes selected from rheumatoid arthritis, multiple sclerosis, psoriasis, psoriatic arthritis, Crohn's disease, and Hashimoto's thyroiditis; and atopic dermatitis. 
Kristalni oblik prema bilo kojem od zahtjeva 1 do 10, ili farmaceutski sastav prema zahtjevu 11, naznačen time, da se upotrebljava za prevenciju ili liječenje bolesti ili poremećaja odabranih iz skupine koja se sastoji od sljedećih: odbacivanje transplantiranih organa kao što su bubreg, jetra, srce i pluća; usadak protiv stanice domaćina uzrokovan transplantacijom matične stanice; autoimuni sindromi odabrani od sljedećih: reumatoidni artritis, multipla skleroza, psorijaza, psorijatični artritis, Chronova bolest i Hashimotoov tiroiditis; te atopijski dermatitis.
a topcoat being in contact with the absorptive layer, wherein the topcoat has a permeability of greater than 5.0×10-18 m2, wherein the topcoat comprises calcium carbonate. 
završni premaz u doticaju s apsorpcijskim slojem, pri čemu završni premaz ima propusnost veću od 5.0x10-18 m2, pri čemu završni premaz sadrži kalcijev karbonat.
drying the absorptive layer and the topcoat, wherein the absorptive layer and the topcoat are either dried simultaneously or the absorptive layer is dried after step b) and before applying the topcoat according to step c) wherein the topcoat has a permeability of greater than 5.0×10-18 m2 and comprises calcium carbonate, and wherein the absorptive layer has an absorption rate from 1×10-5 ms-0.5 to 1×10-3 ms-0.5 and/or a volume uptake from 30 to 95 % by volume relative to the total volume of the absorptive layer. 
sušenje apsorpcijskog sloja i završnog premaza, pri čemu se apsorpcijski sloj i završni premaz suše istodobno ili se apsorpcijski sloj suši nakon koraka b) i prije nanošenja završnog premaza u koraku c) pri čemu završni premaz ima propusnost veću od 5.0×10-18 m2 i sadrži kalcijev karbonat, i pri čemu apsorpcijski sloj ima stupanj upijanja od 1×10-5 ms-0.5 do 1×10-3 ms-0.5 i/ili unos volumena od 30 do 95 % volumena u odnosu na ukupni volumen apsorpcijskog sloja.
Alisporivir for use according to claim 1 comprising administering an effective amount of alisporivir and optionally administering to the patient an interferon or a direct antiviral agent. 
Alisporivir za uporabu prema zahtjevu 1, naznačen time, da se pacijentu primjenjuje učinkovita količina alisporivira i opcijski se daje interferon ili direktno antivirusno sredstvo.
An antibody or antigen-binding portion of claim 13 for use in a method for treating according to claim 13, wherein the viral infection is mediated by human immunodeficiency virus (HIV), hepatitis C virus (HCV), herpes simplex virus type I (HSV-1) or the Severe Acute Respiratory Syndrome (SARS) virus. 
Antitijelo ili antigen-vežući dio prema patentnom zahtjevu 13 za uporabu u postupku za tretman prema patentnom zahtjevu 13, gdje je virusna infekcija posredovana preko virusa humane imunodeficijencije (HIV), virusa hepatitisa C (HCV), herpes simpleks virusa tipa I (HSV-1) ili virusa teškog akutnog respiratornog sindroma (SARS).
A bispecific molecule comprising the antibody or antigen-binding portion thereof of any one of claims 1 to 6, linked to a second functional moiety having a different binding specificity than said antibody or antigen-binding portion. 
Bispecifična molekula koja sadrži antitijelo ili antigen-vežući dio prema bilo kojem od patentnih zahtjeva 1 do 4, vezana za drugu funkcionalnu grupu koja ima različitu specifičnost vezanja od navedenog antitijela ili antigen-vežućeg dijela.
A composition comprising the antibody or antigen-binding portion thereof of any one of claims 1 to 6, the immunoconjugate of claim 7 or the bispecific molecule of claim 8, and a pharmaceutically acceptable carrier. 
Kompozicija koja sadrži antitijelo ili antigen-vežući dio prema bilo kojem od patentnih zahtjeva 1 do 4, imunokonjugat prema patentnom zahtjevu 6 ili bispecifičnu molekulu prema patentnom zahtjevu 7, i farmaceutski prihvatljiv nosač.
The reactor (3; 3 ′) as claimed in claim 3 wherein the reactor (3; 3 ′) is made of stainless steel and has insulated inside and outside surface to eliminate heat loss. 
Reaktor (3, 3'), prema zahtjevu 3, naznačen time da je reaktor (3, 3') napravljen od nehrđajučeg čelika i ima izoliranu unutarnju i vanjsku stijenku, da bi se izbjegao gubitak topline.
The system (3; 3 ′) as claimed in claim 14 wherein said connection is provided with said valves (4 ′). 
Sustav (3, 3’) prema zahtjevu 13, naznačen time da će reaktori biti povezani s ventilima (4’).
Ra and Rb are independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, saturated and partially unsaturated C3-C6 cycloalkyl, saturated and partially unsaturated C1-C6 heterocyclyl, Vn-aryl, or Vn-heteroaryl, wherein said alkyl, alkenyl, alkynyl, saturated or partially unsaturated Vn-cycloalkyl, saturated or partially unsaturated Vn-heterocyclyl, Vn-aryl, and Vn-heteroaryl are optionally substituted with one or more OH; 
Ra i Rb su nezavisno H, C1-C6 alkil, C2-C6 alkenil, C2-C6 alkinil, zasićeni ili djelomično nezasićeni Vn-C3-C6 cikloalkil, zasićeni ili djelomično nezasićeni Vn-C1-C6 heterociklil, Vn-aril, ili Vn-heteroaril, gdje su taj alkil, alkenil, alkinil, zasićeni ili djelomično nezasićeni Vn-cikloalkil, zasićeni ili djelomično nezasićeni Vn-heterociklil, Vn-aril, i Vn-heteroaril po izboru supstituirani jednom ili više OH skupina;
R8, R9 and R10 are independently H, C1-C6 alkyl, or saturated and partially unsaturated C1-C6 heterocyclyl, wherein said alkyl and heterocyclyl are optionally substituted with one or more groups independently selected from C1-C6 alkyl, saturated and partially unsaturated C1-C6 heterocyclyl, ORa, NRaRb, C(=O)ORa and C(=O)NRaRb, or R8 and R9 together with the atoms to which they are attached form a saturated or partially unsaturated heterocyclic ring; 
, R9 i R10 su nezavisno H, C1-C6 alkil, ili zasićeni ili djelomično nezasićeni C1-C6 heterociklil, gdje su taj alkil i heterociklil po izboru supstituirani jednom ili više skupina koje se nezavisno biraju između C1-C6 alkil, zasićeni ili djelomično nezasićeni C1-C6 heterociklil, ORa, NRaRb, C(=O)ORa i C(=O)NRaRb, ili R8 i R9 zajedno s atomima za koje su spojeni formiraju zasićeni ili djelomično nezasićeni heterociklički prsten;
or R12 and R13 together with the atoms to which they are attached form an heteroaryl ring; 
ili R12 i R13 zajedno s atomima za koje su spojeni formiraju heteroarilni prsten;
contacting a compound (C) comprising one or more groups Si-H with a phosphorous based catalyst in the presence of a base in water as solvent, thereby forming hydrogen and a by-product (C1); 
kontaktiranja spoja (C) koji sadrži jednu ili više skupina Si-H s katalizatorom na bazi fosfora u prisutnost lužine u vodi kako otapala, dobivajući tako vodik i nusproizvod (C1);
wherein said phosphorous based catalyst is selected from: 
naznačeno time da navedeni katalizator na bazi fosfora je odabran od:
and X2 together form with the phosphorous atom to which they are attached a 3 to 10 membered heterocycloalkyl optionally substituted by Rd; and X3 is as defined above or 
i X2 zajedno čine s atomom fosfora na koji su vezani 3 do 10-člani heterocikloalkil opcionalno supstituiran s Rd; i X3 je definiran gore ili
a polymer-supported catalyst bearing one or more groups RaRb(P=O)-, RaRb being as defined hereabove; ii) recovering the obtained hydrogen. 
polimerom potpomognuti katalizator koji nosi jednu ili više skupina RaRb (P=O)-, RaRb su definirane gore; ii) obnova dobivenog vodika.
contacting the by-product (C1) with an acyl halide; 
kontaktiranje nusproizvoda (C1) s acil halidom;
contacting the obtained product with a metal hydride, thereby regenerating the compound (C). 
kontaktiranje dobivenog proizvoda s metalnim hidridom, obnavljajući tako spoj (C).
A composition comprising a compound (C), a phosphorous based catalyst, a base and water as solvent as defined in any of claims 1 to 12. 
Sastav koji sadrži spoj (C), katalizator na bazi fosfora, lužinu u vodi kao otapalo kako su definirani u bilo kojem patentnom zahtjevu od 1 do 12.
A reaction mixture inlet, said mixture comprising a compound (C), a base in water as a solvent; 
reakcija ulazne mješavine, navedena mješavina sadrži spoj (C), lužinu u vodi kao otapalo;
a by-product collector; and 
kolektor nusproizvoda; i
The device of claim 15, further comprising a mixing chamber for mixing the compound (C) with the base in water as a solvent, wherein the mixing chamber is connected to the reaction chamber. 
Uređaj prema patentnom zahtjevu 15, naznačen time da nadalje sadrži komoru za miješanje za miješanje spoja (C) s lužinom u vodi kao otapalom, gdje je komora za miješanje povezana s reakcijskom komorom.
an internal wall separating said chamber into two distinct compartments, namely: 
unutarnji zid koji razdvaja navedenu komoru na dva različita odjeljka, preciznije:
a first compartment containing the reaction mixture to be introduced in the reaction chamber; and 
prvi odjeljak koji sadrži reakcijsku koju će se uvesti u reakcijsku komoru; i